Biomedical Engineering Reference
In-Depth Information
[61]
Carroll, B. J., “Dexamethasone Suppression Test: A Review of Contemporary Confusion,”
J. Clin. Psychiatry,
Vol. 46, February 1985, pp. 13-24.
[62]
Howland, R. H., and M. E. Thase, “Biological Studies of Dysthymia,”
Biol. Psychiatry,
Vol. 30, August 1, 1991, pp. 283-304.
[63]
Kupfer, D. J., et al., “EEG Sleep Profiles and Recurrent Depression,”
Biol. Psychiatry,
Vol. 30, October 1, 1991, pp. 641-655.
[64]
Rush, A. J., and J. E. Weissenburger, “Melancholic Symptom Features and DSM-IV,”
Am.
J. Psychiatry,
Vol. 151, April 1994, pp. 489-498.
[65]
Copolov, D., and J. Crook,“Biological Markers and Schizophrenia,”
Aust. N. Z. J. Psychia-
try
, Vol. 34 Suppl., November 2000, pp. S108-S112.
[66]
Lee, K. H., and L. M. Williams, “Eye Movement Dysfunction as a Biological Marker of
Risk for Schizophrenia,”
Aust. N. Z. J. Psychiatry,
Vol. 34, Suppl., November 2000,
pp. S91-S100.
[67]
Crowell, S. E., et al., “Autonomic Correlates of Attention-Deficit/Hyperactivity Disorder
and Oppositional Defiant Disorder in Preschool Children,”
J. Abnorm. Psychol.,
Vol. 115,
February 2006, pp. 174-178.
[68]
Kraemer, H. C., S. K. Schultz, and S. Arndt, “Biomarkers in Psychiatry: Methodological
Issues,”
Am. J. Geriatr. Psychiatry,
Vol. 10, November-December 2002, pp. 653-659.
[69]
Jacobs, D. J., et al.,
Practice Guidelines for the Assessment and Treatment of Patients with
Suicidal Behaviors,
Arlington, VA: American Psychiatric Association, 2003.
[70]
Iosifescu, D. V., et al., “Pretreatment Frontal EEG and Changes in Suicidal Ideation During
SSRI Treatment in Major Depressive Disorder,”
Acta Psychiatr. Scand.,
Vol. 117, April
2008, pp. 271-276.
[71]
Pompili, M., et al., “White Matter Hyperintensities and Their Associations with Suicidality
in Patients with Major Affective Disorders,”
Eur. Arch. Psychiatry Clin. Neurosci.,
Vol. 257, December 2007, pp. 494-499.
[72]
Laje, G., et al., “Genetic Markers of Suicidal Ideation Emerging During Citalopram Treat-
ment of Major Depression,”
Am. J. Psychiatry,
Vol. 164, October 2007, pp. 1530-1538.
[73]
Perlis, R., et al., “Association Between Treatment-Emergent Suicidal Ideation with
Citalopram and Polymorphisms Near Cyclic Adenosine Monophosphate Response Ele-
ment Binding Protein in the STAR*D Study,”
Arch. Gen. Psychiatry,
Vol. 64, June 2007,
pp. 689-697.
[74]
Nierenberg, A. A., et al., “Early Nonresponse to Fluoxetine as a Predictor of Poor 8-Week
Outcome,”
Am. J. Psychiatry,
Vol. 152, October 1995, pp. 1500-1503.
[75]
Trivedi, M. H., et al., “Evaluation of Outcomes with Citalopram for Depression Using
Measurement-Based Care in STAR*D: Implications for Clinical Practice,”
Am. J. Psychia-
try
, Vol. 163, January 2006, pp. 28-40.
[76]
Sussman, N., “Translating Science into Service: Lessons Learned from the Sequenced Treat-
ment Alternatives to Relieve Depression (STAR*D) Study,”
Prim. Care Companion J. Clin.
Psychiatry
, Vol. 9, 2007, pp. 331-337.
[77]
Trivedi, M. H., et al., “Maximizing the Adequacy of Medication Treatment in Controlled
Trials
and
Clinical
Practice:
STAR(*)D
Measurement-Based
Care,”
Neuropsychopharmacology
, Vol. 32, December 2007, pp. 2479-2489.
[78]
Insel, T., “Identification of the Best Genomic-Neuromarker Profiles for Brain Related Per-
sonalized Medicine,”
Society for Neuroscience Annual Meeting
, San Diego, CA, November
5, 2007.
[79]
Cook, I. A., and A. F. Leuchter, “Prefrontal Changes and Treatment Response Prediction in
Depression,”
Semin. Clin. Neuropsychiatry,
Vol. 6, April 2001, pp. 113-120.
[80]
Cook, I. A., et al., “Early Changes in Prefrontal Activity Characterize Clinical Responders
to Antidepressants,”
Neuropsychopharmacology
, Vol. 27, July 2002, pp. 120-131.
[81]
Cook, I. A., et al., “Changes in Prefrontal Activity Characterize Clinical Response in SSRI
Nonresponders: A Pilot Study,”
J. Psychiatr. Res.,
Vol. 39, September 2005, pp. 461-466.
Search WWH ::
Custom Search